{"analyses":[{"ciLowerLimit":"14.0","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"23.2","estimateComment":"Belzutifan minus Everolimus","groupIds":["OG000","OG001"],"nonInferiorityComment":"P-value, difference in percentage and associated 95% CI were calculated using Miettinen \\& Nurminen method stratified by IMDC Risk Category and Number of prior VEGF/VEGF-Receptor Targeted Therapies for RCC.","nonInferiorityType":"SUPERIORITY","pValue":"<0.00001","pValueComment":"One-sided p-value for testing. H0: difference in % = 0 versus H1: difference in % \\> 0.","paramType":"Difference in Percentage","paramValue":"18.4","statisticalMethod":"Miettinen & Nurminen"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"17.8","upperLimit":"26.5","value":"21.9"},{"groupId":"OG001","lowerLimit":"1.9","upperLimit":"5.9","value":"3.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"374"},{"groupId":"OG001","value":"372"}],"units":"Participants"}],"description":"ORR is defined as the percentage of participants who have a complete response (CR: Disappearance of all target lesions) or a partial response (PR: At least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1. The percentage of participants who experience a CR or PR as assessed by blinded independent central review based on RECIST 1.1 is presented here.","dispersionType":"95% Confidence Interval","groups":[{"description":"Randomized participants received 120 mg of belzutifan orally once daily (QD), until disease progression or discontinuation.","id":"OG000","title":"Belzutifan"},{"description":"Randomized participants received 10 mg of Everolimus orally QD, until disease progression or discontinuation.","id":"OG001","title":"Everolimus"}],"paramType":"NUMBER","populationDescription":"Per protocol, the analysis population consisted of all randomized participants based on the treatment group to which they were randomized. Per protocol, participants enrolled in the Safety Run-In were not randomized and not included in the protocol-specified analyses for any of the outcome measures.","reportingStatus":"POSTED","timeFrame":"Up to approximately 31 months","title":"Objective Response Rate (ORR) Per RECIST 1.1 as Assessed by BICR","type":"SECONDARY","unitOfMeasure":"Percentage of Participants"}